SG144712A1 - Nordihydroguaiartic derivaties for use in treatment of tumors - Google Patents

Nordihydroguaiartic derivaties for use in treatment of tumors

Info

Publication number
SG144712A1
SG144712A1 SG200402053-3A SG2004020533A SG144712A1 SG 144712 A1 SG144712 A1 SG 144712A1 SG 2004020533 A SG2004020533 A SG 2004020533A SG 144712 A1 SG144712 A1 SG 144712A1
Authority
SG
Singapore
Prior art keywords
tumors
treatment
nordihydroguaiartic
derivaties
methods
Prior art date
Application number
SG200402053-3A
Other languages
English (en)
Inventor
Ru Chih C Huang
Jonathan D Heller
Chih-Chuan Chang
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG144712A1 publication Critical patent/SG144712A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG200402053-3A 1999-10-15 2000-10-16 Nordihydroguaiartic derivaties for use in treatment of tumors SG144712A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/418,594 US6214874B1 (en) 1999-10-15 1999-10-15 Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Publications (1)

Publication Number Publication Date
SG144712A1 true SG144712A1 (en) 2008-08-28

Family

ID=23658774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200402053-3A SG144712A1 (en) 1999-10-15 2000-10-16 Nordihydroguaiartic derivaties for use in treatment of tumors

Country Status (10)

Country Link
US (4) US6214874B1 (enExample)
EP (1) EP1231914B1 (enExample)
JP (2) JP4062664B2 (enExample)
CN (1) CN1309381C (enExample)
AT (1) ATE350030T1 (enExample)
AU (1) AU783015C (enExample)
CA (1) CA2387873C (enExample)
DE (1) DE60032795T2 (enExample)
SG (1) SG144712A1 (enExample)
WO (1) WO2001028494A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
EP1631269A4 (en) * 2003-05-20 2007-09-12 Erimos Pharmaceutical Llp METHOD AND COMPOSITIONS FOR DISTRIBUTING CATECHOLIC BUTANESE FOR THE TREATMENT OF ADIPOSITAS
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
ATE421545T1 (de) * 2003-08-07 2009-02-15 Huntsman Adv Mat Switzerland Photovernetzbare polyurethane
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
EP1748767B1 (en) * 2004-05-28 2011-12-28 Unigen, Inc. 1-(3-methyl-2,4-dimethoxyphenyl)-3-(2',4'-dihydroxyphenyl)-propane as a potent tyrosinase inhibitor
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
WO2006041902A2 (en) * 2004-10-06 2006-04-20 Johns Hopkins University Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
JP5069130B2 (ja) * 2005-01-27 2012-11-07 エリモス・ファーマスーティカルズ・エルエルシー Ｎｄｇａ化合物を包含するカテコールブタンの送達のための経口用製剤
JP2009528294A (ja) * 2006-02-23 2009-08-06 エリモス・ファーマスーティカルズ・エルエルシー インフルエンザウイルス感染症の治療方法
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
CN101547689B (zh) * 2006-10-02 2014-02-26 埃里莫斯医药品有限公司 通过醚键和氨基甲酸酯键四取代的ndga衍生物、它们的合成方法和药学用途
WO2008088806A1 (en) * 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
DK2150218T3 (en) * 2007-05-11 2016-09-05 Convatec Technologies Inc Ostomy device
KR101988329B1 (ko) * 2008-07-21 2019-06-12 유니젠, 인크. 일련의 피부-화이트닝(라이트닝) 화합물
KR20100011963A (ko) * 2008-07-25 2010-02-03 국립암센터 Ｎｄｇａ를 포함하는 트란스글루타미나제 억제용 조성물
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
JP6216312B2 (ja) 2011-03-24 2017-10-18 ユニゲン・インコーポレーテッド ジアリールプロパンを調製するための化合物及び方法
US9084779B2 (en) 2011-05-31 2015-07-21 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
AU2013292576A1 (en) * 2012-07-18 2015-02-05 The Johns Hopkins University Methods for inhibition of BNIP3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
MX391317B (es) 2017-02-17 2025-03-21 Promotora Tecnica Ind S A De C V Composicion mejorada a base de acido norhidroguayaretico.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) * 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) * 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
US5559149A (en) * 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5646186A (en) * 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US6071949A (en) * 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INHIBITORS OF ADENOSINE 3Æ,5Æ-CYCLE MONOPHOSPHATE PHOSPHDIESTERASE F *
ROM SCHISANDRA CHINERSIS AND THE STRUCTURE ACTIVITY RELATIONSHIP OF LI *

Also Published As

Publication number Publication date
US6417234B1 (en) 2002-07-09
AU783015C (en) 2006-08-24
EP1231914B1 (en) 2007-01-03
WO2001028494A3 (en) 2002-01-10
US6958411B2 (en) 2005-10-25
JP4062664B2 (ja) 2008-03-19
WO2001028494A9 (en) 2002-08-01
HK1050860A1 (en) 2003-07-11
CN1391471A (zh) 2003-01-15
JP2003511477A (ja) 2003-03-25
EP1231914A4 (en) 2004-04-14
CA2387873C (en) 2008-12-30
US20050267208A1 (en) 2005-12-01
CA2387873A1 (en) 2001-04-26
JP2008019278A (ja) 2008-01-31
ATE350030T1 (de) 2007-01-15
DE60032795D1 (de) 2007-02-15
CN1309381C (zh) 2007-04-11
US6214874B1 (en) 2001-04-10
DE60032795T2 (de) 2007-11-08
WO2001028494A2 (en) 2001-04-26
US20030065016A1 (en) 2003-04-03
EP1231914A2 (en) 2002-08-21
AU783015B2 (en) 2005-09-15
AU1207501A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
FR2794744B1 (fr) Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
HUP0102563A3 (en) Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation
EE200000366A (et) Seade ja meetod keha kudede ravimiseks elektri või ravimitega
TR200102711T2 (tr) Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
MY138883A (en) Use of asiatic acid for treatment of cencer
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
WO1999044608A8 (en) New use
PL341151A1 (en) Substituted products of condensation of n-benzyl-3-indenylacetamides with heterocyclic aldehydes for use in treating neoplastic diseases
GB9521608D0 (en) Pharmaceutical composition
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
AU7856100A (en) Methods for treating solid tumors with irradiation and bacteria
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
AU734696B2 (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
ZA978772B (en) N-(2-benzothiazolyl)-1-piperidineethanamine derivatives, their preparation and their use in therapy.
JO2199B1 (en) Replaced pyrrols
AU5672000A (en) Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases and method for selecting more effective therapeutic agents for the therapy thereof
GB9723824D0 (en) Cytostatic agents
MXPA02004704A (es) Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo.
AU2001291256A1 (en) Methods and compositions for the identification, assessment and therapy of human cancers
AU4486500A (en) Therapeutic compositions and methods for treating tumors